34 results on '"Dierks, Elizabeth A."'
Search Results
2. Discovery and Optimization of Aryl Piperidinone Ureas as Selective Formyl Peptide Receptor 2 Agonists.
3. Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction
4. Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor Agonist Treatment
5. Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
6. Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders
7. Structure–activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4′ and C6 variations
8. MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity
9. Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure–Function Post Myocardial Infarction
10. Discovery of 12(BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
11. Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists
12. Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
13. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
14. Variable forms of soluble guanylyl cyclase: protein-ligand interactions and the issue of activation by carbon monoxide
15. Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole
16. Demonstration of the role of scission of the proximal histidine - iron bond in the activation of soluble guanylyl cyclase through metalloporphyrin substitution studies
17. Studies of the heme coordination and ligand binding properties of soluble guanylyl cyclase (sGC): characterization of Fe(II)sGC and Fe(II)sGC(CO) by electronic absorption and magnetic circular dichroism spectroscopies and failure of CO to activate the enzyme
18. Application of ultrasound‐guided cholecystocentesis to the evaluation of the metabolite profiling in bile of dogs and cynomolgus monkeys
19. Single-species Allometric Scaling: A Strategic Approach to Support Drug Discovery
20. Assessment of pre-operative maropitant citrate use in macaque (Macaca fasicularis & Macaca mulatta)neurosurgical procedures
21. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
22. Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode
23. Abstract TMP117: Preclinical and Early Clinical Characterization of a Parenterally Administered Direct Factor XIa Inhibitor
24. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists
25. Assessment of pre‐operative maropitant citrate use in macaque (<italic>Macaca fasicularis & Macaca mulatta)</italic> neurosurgical procedures.
26. Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake
27. Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent
28. The Catalytic Site of Cytochrome P4504A11 (CYP4A11) and Its L131F Mutant
29. The Deactivation of Soluble Guanylyl Cyclase by Redox-Active Agents,
30. Demonstration of the Role of Scission of the Proximal Histidine−Iron Bond in the Activation of Soluble Guanylyl Cyclase through Metalloporphyrin Substitution Studies
31. Nitric oxide (NO•), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase
32. Prodrug Strategy to Address Impaired Oral Absorption of a Weakly Basic TYK2 Inhibitor Caused by a Gastric Acid-Reducing Agent.
33. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
34. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.